Adovate Granted New U.S. Patent for Therapeutic Uses of A2B Receptor Antagonists
New Patent Expands Adovate’s Intellectual Property Portfolio Around A2B-Targeted Therapies for Asthma, Cancer, and Inflammatory Conditions
Charlottesville, VA – May 7, 2025 – Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company developing novel therapeutics targeting adenosine receptors involved in major diseases, today announced that Patent Number 12,269,828 B2 was issued by the United States Patent and Trademark Office.
This newly issued patent covers therapeutic uses of the Company’s lead molecule ADO-5030 and thousands of other novel molecules with similar chemical structures. Specifically, the patent covers methods for treating diseases such as asthma, cancer (including breast and bladder cancer), inflammatory bowel disease, diabetic retinopathy, and other conditions for which antagonism of the adenosine 2B receptor (“A2BR”) offers therapeutic potential.
“This patent provides further protection for our lead molecule, ADO-5030, and our pipeline of best-in-class compounds in the areas of asthma, cancer and other disease indications,” said William Stilley, CEO of Adovate. “It demonstrates Adovate’s leadership in the A2BR space and fortifies Adovate’s dominance in an area of adenosine chemistry we believe is strategic for developing A2BR blockers. It also adds to our patent portfolio, which has patents issuing world-wide.”
About Adovate, LLC
Adovate is a biopharmaceutical company focused on inventing and developing novel, best-in-class drug candidates targeting the adenosine receptors. Additional information is available at www.adovate.com.
Forward Looking Statements
This communication contains certain “forward-looking statements” within the meaning of applicable securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptionsand are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by, or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements includethe foregoing. The forward-looking statements include statements regarding Adovate developing novel therapeutic uses of A2B receptor Antagonists including for treating diseases such as asthma, cancer (including breast and bladder cancer), inflammatory conditions such as inflammatory bowel disease, diabetic retinopathy, and other conditions, Adovate developing thousands of other novel molecules with similar chemical structures, and the new patent demonstrating Adovate’s leadership in the A2BR space and fortifying Adovate’s dominance in an area of adenosine chemistry which Adovate believes is strategic for developing A2BR blockers. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, Adovate’s ability to develop novel, patentable, next generation molecules targeting specific adenosine receptors which will create significant advancements in treatments for other diseases, and Adovate inventing and developing best-in-class drug candidates targeting adenosine receptors. These risks should not be construed as exhaustive. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations:
Media Relations: